Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Vaccine for COVID-19 Protection and Vaccine Efficacy Enhancement
NCT05507671Phase 3Active, not recruiting
- Sponsor
- Fundação Oswaldo Cruz
- Start
- May 2021
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BCG vaccine with Placebo (2 arms). Primary endpoints: Incidence of SARS-CoV-2 infection at 6 months, Incidence of illness by COVID-19 at 6 months and 2 more. Started May 2021; status: active, not recruiting.
02
Drugs
bcg vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05507671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507671.